FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2621462012> ?p ?o ?g. }

• W2621462012 endingPage "719" @default.
• W2621462012 startingPage "719" @default.
• W2621462012 abstract "Compared with the general population, patients with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Previous interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects.To determine the effects of the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders.This randomized clinical double-blind trial enrolled participants at 2 clinical sites in Denmark. Of 214 eligible participants with a schizophrenia spectrum disorder, 103 were randomized to liraglutide or placebo. Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes. Data were collected from May 1, 2013, through February 25, 2016.Treatment for 16 weeks with once-daily subcutaneous injection of liraglutide or placebo. Trial drug therapy was titrated during the first 2 weeks of the study.The primary end point was change in glucose tolerance estimated by a 75-g oral glucose tolerance test result. Secondary end points included change in body weight and cardiometabolic parameters.Of the 103 patients undergoing randomization (60 men [58.3%] and 43 women [41.7%]), 97 were included in the efficacy analysis, with a mean (SD) age of 42.5 (10.5) years and mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) of 33.8 (5.9). The liraglutide and placebo groups had comparable characteristics (mean [SD] age, 42.1 [10.7] vs 43.0 [10.5] years; 30 men in each group; mean [SD] body mass index, 33.7 [5.1] vs 33.9 [6.6]). A total of 96 randomized participants (93.2%) completed the trial. Glucose tolerance improved in the liraglutide group compared with the placebo group (P < .001). Altogether, 30 liraglutide-treated participants (63.8%) developed normal glucose tolerance compared with 8 placebo-treated participants (16.0%) (P < .001; number needed to treat, 2). Body weight decreased with liraglutide compared with placebo (-5.3 kg; 95% CI, -7.0 to -3.7 kg). Reductions in waist circumference (-4.1 cm; 95% CI, -6.0 to -2.3 cm), systolic blood pressure (-4.9 mm Hg; 95% CI, -9.5 to -0.3 mm Hg), visceral fat (-250.19 g; 95% CI, -459.9 to -40.5 g), and low-density lipoprotein levels (-15.4 mg/dL; 95% CI, -23.2 to -7.7 mg/dL) occurred with liraglutide compared with placebo. Adverse events with liraglutide affected mainly the gastrointestinal tract.Liraglutide significantly improved glucose tolerance, body weight, and cardiometabolic disturbances in patients with schizophrenia spectrum disorders treated with clozapine or olanzapine.clinicaltrials.gov Identifier: NCT01845259." @default.
• W2621462012 created "2017-06-15" @default.
• W2621462012 creator A5001609083 @default.
• W2621462012 creator A5001762767 @default.
• W2621462012 creator A5002435448 @default.
• W2621462012 creator A5004120950 @default.
• W2621462012 creator A5018017351 @default.
• W2621462012 creator A5026909071 @default.
• W2621462012 creator A5033355863 @default.
• W2621462012 creator A5040558708 @default.
• W2621462012 creator A5044660787 @default.
• W2621462012 creator A5056944189 @default.
• W2621462012 creator A5065962810 @default.
• W2621462012 creator A5075364098 @default.
• W2621462012 creator A5078539617 @default.
• W2621462012 creator A5078765891 @default.
• W2621462012 creator A5085434984 @default.
• W2621462012 creator A5088275838 @default.
• W2621462012 date "2017-07-01" @default.
• W2621462012 modified "2023-10-01" @default.
• W2621462012 title "Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder" @default.
• W2621462012 cites W1742833546 @default.
• W2621462012 cites W1887914370 @default.
• W2621462012 cites W1933606243 @default.
• W2621462012 cites W1959592008 @default.
• W2621462012 cites W1968434622 @default.
• W2621462012 cites W1973933734 @default.
• W2621462012 cites W1980621268 @default.
• W2621462012 cites W1994320162 @default.
• W2621462012 cites W2009832071 @default.
• W2621462012 cites W2014026290 @default.
• W2621462012 cites W2021914080 @default.
• W2621462012 cites W2030795765 @default.
• W2621462012 cites W2031094750 @default.
• W2621462012 cites W2061549173 @default.
• W2621462012 cites W2073235937 @default.
• W2621462012 cites W2083168772 @default.
• W2621462012 cites W2085360366 @default.
• W2621462012 cites W2087706575 @default.
• W2621462012 cites W2092025665 @default.
• W2621462012 cites W2106036385 @default.
• W2621462012 cites W2110608362 @default.
• W2621462012 cites W2111105929 @default.
• W2621462012 cites W2120522789 @default.
• W2621462012 cites W2124239868 @default.
• W2621462012 cites W2128374924 @default.
• W2621462012 cites W2138691846 @default.
• W2621462012 cites W2145456604 @default.
• W2621462012 cites W2148688487 @default.
• W2621462012 cites W2149288810 @default.
• W2621462012 cites W2152835319 @default.
• W2621462012 cites W2153399820 @default.
• W2621462012 cites W2157799751 @default.
• W2621462012 cites W2161376690 @default.
• W2621462012 cites W2161797688 @default.
• W2621462012 cites W2169855023 @default.
• W2621462012 cites W2196942236 @default.
• W2621462012 cites W2277996843 @default.
• W2621462012 cites W2327775854 @default.
• W2621462012 cites W2425644022 @default.
• W2621462012 cites W2466123555 @default.
• W2621462012 cites W2515404667 @default.
• W2621462012 cites W2527926557 @default.
• W2621462012 cites W4213156113 @default.
• W2621462012 cites W4292528167 @default.
• W2621462012 cites W807162506 @default.
• W2621462012 doi "https://doi.org/10.1001/jamapsychiatry.2017.1220" @default.
• W2621462012 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5710254" @default.
• W2621462012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28601891" @default.
• W2621462012 hasPublicationYear "2017" @default.
• W2621462012 type Work @default.
• W2621462012 sameAs 2621462012 @default.
• W2621462012 citedByCount "125" @default.
• W2621462012 countsByYear W26214620122017 @default.
• W2621462012 countsByYear W26214620122018 @default.
• W2621462012 countsByYear W26214620122019 @default.
• W2621462012 countsByYear W26214620122020 @default.
• W2621462012 countsByYear W26214620122021 @default.
• W2621462012 countsByYear W26214620122022 @default.
• W2621462012 countsByYear W26214620122023 @default.
• W2621462012 crossrefType "journal-article" @default.
• W2621462012 hasAuthorship W2621462012A5001609083 @default.
• W2621462012 hasAuthorship W2621462012A5001762767 @default.
• W2621462012 hasAuthorship W2621462012A5002435448 @default.
• W2621462012 hasAuthorship W2621462012A5004120950 @default.
• W2621462012 hasAuthorship W2621462012A5018017351 @default.
• W2621462012 hasAuthorship W2621462012A5026909071 @default.
• W2621462012 hasAuthorship W2621462012A5033355863 @default.
• W2621462012 hasAuthorship W2621462012A5040558708 @default.
• W2621462012 hasAuthorship W2621462012A5044660787 @default.
• W2621462012 hasAuthorship W2621462012A5056944189 @default.
• W2621462012 hasAuthorship W2621462012A5065962810 @default.
• W2621462012 hasAuthorship W2621462012A5075364098 @default.
• W2621462012 hasAuthorship W2621462012A5078539617 @default.
• W2621462012 hasAuthorship W2621462012A5078765891 @default.
• W2621462012 hasAuthorship W2621462012A5085434984 @default.
• W2621462012 hasAuthorship W2621462012A5088275838 @default.
• W2621462012 hasBestOaLocation W26214620122 @default.

• next